WANG Nan
Principal Investigator
Education Background
Wang Nan received his doctoral degree from the Academy of Military Medical Sciences in 1994, and his master's degree from the Fourth Military Medical University in 1989. He graduated from the Fourth Military Medical University with a bachelor's degree in 1986.
Work Experience
From 1996 to 2001, Wang conducted postdoctoral research at Thomas Jefferson University and Sloan-Kettering Cancer Center in the United States, and at the Cancer Institute of the Chinese Academy of Medical Sciences.
Since 2001, he has been PI at the Institute of Materia Medica.
1. NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL. Cancer Chemotherapy and Pharmacology , 2021, 88:289–306.
2. Dimerization/oligomerization of the extracellular domain of the GLP-1 receptor and the negative cooperativity in its ligand binding revealed by the improved NanoBiT. FASEB Journal , 2020, 34:4348–4368.
3. A New Metal Affinity NCTR 25 Tag as a Better Alternative to the His-tag for the Expression of Recombinant Fused Proteins. Protein Expression and Purification , 2019, 164: 105477.
4. TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers. Biochem Pharmacol , 2018, 155: 510-523.
5. Insulin Chains as Efficient Fusion Tags for Prokaryotic Expression of Short Peptides. Protein Expression and Purification , 2017, 138:46-55.
6. Ubiquitin-like prokaryotic MoaD as a fusion tag for expression of heterologous proteins in Escherichia coli. BMC Biotechnology , 2014, 14(1):5.
7. Prokaryotic Ubiquitin-Like ThiS Fusion Enhances the Heterologous Protein Overexpression and Aggregation in Escherichia coli. PLoS One , 2013, 8(4):e62529.
8. SAHA and curcumin combinations co-enhance histone acetylation in human cancer cells but operate antagonistically in exerting cytotoxic effects. J Asian Nat Prod Res , 2010, 12(5): 335-348.
9. Antitumor effects of a novel sulfur-containing hydroxamate HDAC inhibitor H40. Int J Cancer , 2009, 124(5): 1235-44.
10. Delayed-late activation of a myeloid defensin minimal promoter by retinoids and inflammatory mediators. Leukemia Research , 2004, 28(8): 879-889.
11. Synthesis and cytotoxicity of 3-aryl acrylic amide derivatives of the simplified saframycin-ecteinascidin skeleton prepared from l-dopa. Eur J Med Chem , 2013; 62:670-6.
12. Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues. Eur J Med Chem , 2012;49:239-44.
13. Synthesis and cytotoxicity of (-)-renieramycin G analogs. Bioorganic & medicinal chemistry letters , 2011; 21(5):1419-21.
14. Synthesis of 5(6)-dihydro-OSW-1 analogs bearing three kinds of disaccharides linking at 15-hydroxy and their antitumor activities. Bioorganic & medicinal chemistry letters , 2011; 21(10):2921-4.
15. Synthesis and cytotoxicity of cis-dichloroplatinum (II) complexes of (1S,3S)-1,2,3,4-tetrahydroisoquinolines. European Journal of Medicinal Chemistry , 2011, 46(1):356-363.
16. Chemical conjugation of muramyl dipeptide and paclitaxel to explore the combination of immunotherapy and chemotherapy for cancer. Glycoconj J ,2008; 25(5): 415-25.
17. Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin. J Natl Cancer Inst , 2007; 99(13): 1004-1015.
18. PU.1 and a TTTAAA Element in the Myeloid Defensin-1 Promoter Create an Operational TATA Box That Can Impose Cell Specificity onto TFIID Function. J Immunol , 2006;176(11): 6906-17.
